Literature DB >> 19329799

Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.

Rose A Devasia1, Amondrea Blackman, Carolyn May, Svetlana Eden, Teresa Smith, Nancy Hooper, Fernanda Maruri, Charles Stratton, Ayumi Shintani, Timothy R Sterling.   

Abstract

OBJECTIVES: The aim of this study was to assess the sensitivity, specificity and time to results of mycobacterial growth indicator tube (MGIT) 960, microscopic observation drug susceptibility (MODS) assay and nitrate reductase assay (NRA) compared with the gold standard agar proportion method (PM), and to determine whether there is cross-resistance between older-generation fluoroquinolones and moxifloxacin.
METHODS: Mycobacterium tuberculosis isolates from culture-confirmed tuberculosis patients from 2002 to 2007 were tested for ofloxacin (2 mg/L) resistance by PM and MGIT 960. All isolates from 2005 and 2006 were also tested by MODS and NRA. Ofloxacin-resistant isolates by PM were further tested by all four methods using ciprofloxacin, levofloxacin and moxifloxacin. For each ofloxacin-resistant isolate, two ofloxacin-susceptible isolates were tested against all three fluoroquinolones using all four methods.
RESULTS: Of the 797 M. tuberculosis isolates, 19 (2.4%) were ofloxacin-resistant by PM. MGIT 960 had 100% sensitivity (95% CI, 83%-100%) and specificity (95% CI, 99.5%-100%). Of the 797 isolates, 239 were from 2005 to 2006 and 6 of these (2.5%) were resistant by PM. MODS had 100% sensitivity (95% CI, 61%-100%) and specificity (95% CI, 98%-100%). NRA had 100% sensitivity (95% CI, 61%-100%) and 98.7% specificity (95% CI, 96%-99.6%). The median time to results was shorter using MGIT 960 (8 days), MODS (6 days) or NRA (9 days) compared with PM (21 days) (P < 0.001). All 19 ofloxacin-resistant isolates were resistant to ciprofloxacin, levofloxacin and moxifloxacin by PM.
CONCLUSIONS: MGIT 960, MODS and NRA are sensitive and specific and more rapid than PM for identifying fluoroquinolone resistance in M. tuberculosis. Ofloxacin resistance was associated with cross-resistance to ciprofloxacin, levofloxacin and moxifloxacin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329799      PMCID: PMC2680343          DOI: 10.1093/jac/dkp096

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.

Authors:  Mohamed Abdel Aziz; Abigail Wright; Adalbert Laszlo; Aimé De Muynck; Françoise Portaels; Armand Van Deun; Charles Wells; Paul Nunn; Leopold Blanc; Mario Raviglione
Journal:  Lancet       Date:  2006-12-16       Impact factor: 79.321

2.  Rapid antibiotic susceptibility testing of Mycobacterium tuberculosis: its utility in resource poor settings.

Authors:  A Poojary; G Nataraj; S Kanade; P Mehta; S Baveja
Journal:  Indian J Med Microbiol       Date:  2006-10       Impact factor: 0.985

3.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

4.  Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods.

Authors:  Sulochana Somasundaram; N Chinnambedu Paramasivan
Journal:  Chemotherapy       Date:  2006-05-22       Impact factor: 2.544

5.  Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin.

Authors:  Claudio Piersimoni; Carla Lacchini; Valeria Penati; Elisabetta Iona; Lanfranco Fattorini; Domenico Nista; Diego Zallocco; Gian Pietro Gesu; Luigi Codecasa
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03       Impact factor: 2.803

6.  Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru.

Authors:  L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

7.  In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; A Climent; G Royo
Journal:  Int J Antimicrob Agents       Date:  2001-03       Impact factor: 5.283

8.  Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data.

Authors:  Michelle E Kruijshaar; John M Watson; Francis Drobniewski; Charlotte Anderson; Timothy J Brown; John G Magee; E Grace Smith; Alistair Story; Ibrahim Abubakar
Journal:  BMJ       Date:  2008-05-01

9.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Authors:  R Rustomjee; C Lienhardt; T Kanyok; G R Davies; J Levin; T Mthiyane; C Reddy; A W Sturm; F A Sirgel; J Allen; D J Coleman; B Fourie; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2008-02       Impact factor: 2.373

10.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

View more
  14 in total

Review 1.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

2.  Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?

Authors:  Daniela E Kirwan; María Kathia Cárdenas; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

3.  Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.

Authors:  Yuri F van der Heijden; Fernanda Maruri; Amondrea Blackman; Ed Mitchel; Aihua Bian; Ayumi K Shintani; Svetlana Eden; Jon V Warkentin; Timothy R Sterling
Journal:  Int J Antimicrob Agents       Date:  2013-06-24       Impact factor: 5.283

4.  Direct observation therapy with appropriate treatment regimens was associated with a decline in second-line drug-resistant tuberculosis in Taiwan.

Authors:  J-Y Chien; C-C Tsou; S-T Chien; C-J Yu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-12       Impact factor: 3.267

5.  MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus.

Authors:  J Coronel; M Roper; S Mitchell; E Castillo; N Gamarra; F Drobniewski; G Luna; A Mendoza; D A J Moore
Journal:  Int J Tuberc Lung Dis       Date:  2010-11       Impact factor: 2.373

6.  Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance.

Authors:  A Blackman; S May; R A Devasia; F Maruri; C Stratton; T R Sterling
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-10       Impact factor: 3.267

7.  Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.

Authors:  A P Trollip; D Moore; J Coronel; L Caviedes; S Klages; T Victor; E Romancenco; V Crudu; K Ajbani; V P Vineet; C Rodrigues; R L Jackson; K Eisenach; R S Garfein; T C Rodwell; E Desmond; E J Groessl; T G Ganiats; A Catanzaro
Journal:  Int J Tuberc Lung Dis       Date:  2014-02       Impact factor: 2.373

8.  Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.

Authors:  Ritu Singhal; Paul R Reynolds; Jamie L Marola; L Elaine Epperson; Jyoti Arora; Rohit Sarin; Vithal Prasad Myneedu; Michael Strong; Max Salfinger
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

9.  Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.

Authors:  Irina Kontsevaya; Jim Werngren; Yen Holicka; Kadri Klaos; Anh Tran; Vladyslav Nikolayevskyy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-30       Impact factor: 3.267

10.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.